CBD Oil for Sleep and Cardiovascular Disease: How CBD Addresses Cardiac-Driven Sleep Disruption, Nocturnal Hypertension, and the Heart-Sleep Bidirectional Relationship

Cardiovascular Disease and CBD: Critical Safety Context

Cardiovascular disease management involves medications with narrow therapeutic windows and life-critical dosing precision — warfarin, digoxin, antiarrhythmics, and others where small plasma level changes can cause serious adverse events. CBD's CYP enzyme inhibition (CYP2C9, CYP3A4, CYP2D6, CYP1A2) can significantly alter the plasma levels of cardiac medications metabolized through these pathways. Warfarin (CYP2C9 substrate) interaction with CBD is the most critical: CBD inhibits CYP2C9, elevating warfarin plasma levels and increasing bleeding risk — this interaction has been documented in human case reports. Cardiologist or prescribing physician disclosure is mandatory before initiating CBD if you take any cardiac medication. INR monitoring must be increased for warfarin users during CBD initiation. This guide is for informational purposes only and does not replace physician-supervised cardiovascular management. CBD is not a cardiac medication; it does not treat cardiovascular disease; and it should never be used to substitute for prescribed cardiac medications or to self-manage acute cardiac symptoms. If you experience chest pain, palpitations, severe dyspnea, or other acute cardiac symptoms, seek emergency medical care immediately.

Hypertension: Non-Dipping, OSA, and Nocturnal Sympathetic Activation

Hypertensive patients without heart failure represent the largest cardiovascular population with sleep disruption. The primary mechanisms: nocturnal blood pressure non-dipping from impaired parasympathetic sleep shift; OSA comorbidity (highly prevalent in hypertension — OSA itself causes sustained hypertension through sympathetic activation); and HPA hyperactivation from chronic stress maintaining elevated daytime and nocturnal BP. For hypertensive sleep disruption, CBD's ANS parasympathetic mechanism is most relevant — directly addressing the non-dipping pattern's ANS substrate. The vasodilatory CB1 endothelial mechanism may provide modest antihypertensive contribution. Most hypertension medications have low CYP interaction risk with CBD: amlodipine (CYP3A4 — moderate interaction, physician disclosure warranted); lisinopril/ramipril ACE inhibitors (not CYP-metabolized — low interaction); losartan/valsartan ARBs (CYP2C9/3A4 — moderate); metoprolol/atenolol beta-blockers (CYP2D6 — metoprolol interaction warrants disclosure; atenolol not CYP-metabolized). CPAP therapy (for OSA-driven hypertension) remains the most effective intervention for OSA-comorbid hypertension; CBD is an adjunct within that managed framework. Hypertensive patients should monitor blood pressure during CBD initiation for any unexpected hypotensive effect, particularly with antihypertensive polypharmacy.

Atrial Fibrillation: Sympathetic Trigger Reduction and Sleep Architecture

Atrial fibrillation (AF) — the most common cardiac arrhythmia — has a bidirectional relationship with sleep disruption: AF produces nocturnal palpitations, irregular heartbeat awareness, cardiac anxiety, and sympathetic activation that fragment sleep; and sleep deprivation and OSA independently increase AF burden through sympathetic activation, atrial stretch from OSA-related pressure fluctuations, and inflammatory AF substrate progression. CBD's sympathetic-reducing and HPA-normalizing mechanisms are directly relevant to AF patients: sympathetic activation is a documented AF trigger (adrenergic AF), and reducing the chronic sympathetic tone driving adrenergic AF triggers may modestly reduce AF burden. The cardiac anxiety loop in AF is particularly vicious — nocturnal AF episodes cause intense fear responses that maintain sympathetic tone that perpetuates AF substrate; CBD's 5-HT1A amygdala-reactivity reduction addresses this loop. Critical: AF patients must discuss CBD with their cardiologist before initiating — not only for drug interactions (anticoagulants, antiarrhythmics — see medications section) but because AF management is complex and any supplement that affects cardiac electrophysiology warrants expert oversight. CBD does not treat AF; it addresses the anxiety and sympathetic components of AF-related sleep disruption as an adjunct to standard AF management.

Cardiac Medication Interactions — Cardiologist Disclosure Mandatory

Warfarin (Coumadin) — MOST CRITICAL INTERACTION IN THE SERIES: Warfarin is a CYP2C9 substrate with an extremely narrow therapeutic index — small plasma level changes (INR shifts of 0.5–1.0) meaningfully alter bleeding risk. CBD is a potent CYP2C9 inhibitor and has been documented in human case reports to significantly elevate warfarin levels, causing INR elevation and increased bleeding risk. This is not a theoretical interaction — it has been observed clinically. Mandatory steps: cardiologist and anticoagulation clinic disclosure; INR monitoring every 3–5 days during CBD initiation (rather than the standard weekly or biweekly monitoring); conservative CBD dose initiation (5–10 mg); and immediate INR check if any unusual bleeding, bruising, or symptoms develop after CBD initiation. If INR elevation is detected, CBD dose adjustment or discontinuation and warfarin dose reduction under physician guidance. This interaction does not mean warfarin patients cannot use CBD — it means it requires the most careful physician-monitored initiation of any cardiovascular drug interaction in this guide. The topical cream (zero systemic absorption) avoids this interaction entirely for patients who have only muscular or joint pain indications.

Direct oral anticoagulants (DOACs — apixaban/Eliquis, rivaroxaban/Xarelto, dabigatran/Pradaxa, edoxaban): DOACs are increasingly replacing warfarin for AF anticoagulation and VTE treatment. Rivaroxaban and apixaban are CYP3A4 and P-gp substrates — CBD's CYP3A4 inhibition may elevate their plasma levels; the P-gp inhibitory activity of CBD compounds this. The DOAC interaction is clinically significant but generally less abrupt than the warfarin interaction because DOACs have more predictable pharmacokinetics without the INR monitoring-feedback loop that warfarin requires. Physician disclosure mandatory; cardiologist or anticoagulation specialist should assess whether dose adjustment is appropriate. Dabigatran is primarily a P-gp substrate with minimal CYP metabolism — CBD's P-gp inhibition is the relevant interaction pathway.

Antiarrhythmic medications (amiodarone, flecainide, propafenone, sotalol, dronedarone): Amiodarone — the most commonly used antiarrhythmic — is a potent multi-CYP inhibitor itself (CYP2C9, CYP3A4, CYP2D6) AND a CYP substrate; it has an extremely long half-life (40–55 days) and complex drug interactions. CBD combined with amiodarone represents a dual CYP inhibition scenario — both agents inhibit shared CYP enzymes — increasing amiodarone plasma levels and potentially elevating thyroid, pulmonary, and hepatic toxicity risk. Cardiologist disclosure is essential; amiodarone management is already complex and CBD adds pharmacokinetic complexity that requires specialist oversight. Flecainide and propafenone are CYP2D6 substrates — CBD's CYP2D6 inhibition may elevate their plasma levels. Sotalol is not CYP-metabolized (renally excreted). All antiarrhythmics require cardiologist disclosure before CBD initiation.

Beta-blockers (metoprolol, carvedilol, bisoprolol, atenolol, propranolol): Beta-blockers are foundational therapy in heart failure, post-MI, hypertension, and AF rate control. Metoprolol, carvedilol, and propranolol are CYP2D6 substrates — CBD's CYP2D6 inhibition may elevate their plasma levels, increasing bradycardia and hypotension risk. Atenolol and bisoprolol are not CYP-metabolized (renally excreted) — lower interaction risk. For metoprolol and carvedilol users, physician disclosure is warranted; monitor for increased beta-blockade symptoms (bradycardia, excessive fatigue, dizziness) during CBD initiation. The clinical significance: beta-blockers in heart failure and post-MI are dose-titrated to target heart rates; if CBD elevates metoprolol levels and increases beta-blockade, the effective beta-blockade may exceed the intended dose and target heart rate may drop below therapeutic targets.

Statins (atorvastatin, rosuvastatin, simvastatin, pravastatin): Statins are nearly universal in CAD and high-cardiovascular-risk hypertension. Simvastatin and atorvastatin are CYP3A4 substrates — CBD's CYP3A4 inhibition may elevate their plasma levels, increasing myopathy risk. Rosuvastatin and pravastatin are not significant CYP3A4 substrates (lower interaction risk). For atorvastatin and simvastatin users: physician disclosure warranted; myalgia or muscle weakness emerging after CBD initiation should prompt CK measurement. The practical implication: if a patient on simvastatin experiences CBD-elevated simvastatin levels and develops myopathy, the myopathy pain may add a musculoskeletal sleep disruption to the existing cardiac sleep picture — directly counterproductive.

ACE inhibitors and ARBs (lisinopril, ramipril, enalapril; losartan, valsartan, candesartan): ACE inhibitors are not significantly CYP-metabolized — low pharmacokinetic interaction risk with CBD. ARBs have variable CYP profiles: losartan is CYP2C9 (CBD interaction possible); valsartan and candesartan have minimal CYP metabolism. For losartan users, physician disclosure is appropriate. Pharmacodynamically, CBD's vasodilatory CB1/endothelial mechanism combined with RAAS blockade may produce additive blood pressure reduction — monitor for orthostatic hypotension, particularly in older patients or those with volume depletion.

Digoxin: Digoxin — used for AF rate control and heart failure — is a P-gp substrate with a very narrow therapeutic index; toxicity (nausea, visual disturbance, cardiac arrhythmia) occurs at plasma levels just above the therapeutic range. CBD's P-gp inhibitory activity may elevate digoxin plasma levels. Physician disclosure mandatory; digoxin level monitoring during CBD initiation is appropriate if clinical circumstances suggest increased interaction risk.

Cardiovascular Sleep Dosing Protocol: Physician-Supervised Initiation

Pre-initiation requirements: Cardiologist or prescribing physician disclosure of all cardiac medications before any CBD is taken. For warfarin users: INR baseline measurement and monitoring plan (every 3–5 days during titration) agreed with anticoagulation provider. For antiarrhythmic users: cardiologist awareness and any medication level monitoring plan. For beta-blocker users (particularly metoprolol, carvedilol): resting heart rate baseline and monitoring for bradycardia during initiation.

Starting dose (all cardiac patients): 10 mg nanoemulsion broad spectrum CBD in the evening, with food (to moderate absorption rate and reduce peak plasma concentration). The conservative start is appropriate for cardiac patients given the CYP interaction landscape — starting low establishes the baseline effect of CBD before titrating to higher doses that increase the magnitude of CYP inhibition and drug interaction potential. The 10 mg starting dose provides the HPA and ANS mechanisms at modest intensity while minimizing interaction magnitude during the first 1–2 weeks of monitoring.

Titration: Increase by 5–10 mg every 2 weeks, with a medication monitoring check-in at each increment. Target range: 25–40 mg for most cardiovascular patients (lower than general sleep dosing to maintain conservatism). Higher doses (40–50 mg) may be appropriate for patients on non-interacting cardiac medications (atenolol, pravastatin, ACE inhibitors), as determined with physician guidance.

Timeline and tracking: Cardiac anxiety and sleep onset improvement (5-HT1A, HPA mechanisms): 4–6 weeks. ANS HRV improvement (vagal promotion): 6–8 weeks, trackable with a wearable HRV monitor. Nocturnal blood pressure dipping improvement (ANS mechanism): 8–12 weeks, trackable with a 24-hour ambulatory blood pressure monitor if the physician considers reassessment appropriate. CB2 vascular anti-inflammatory effects: 12+ weeks. Overall minimum evaluation period: 12 weeks, tracking cardiac anxiety ratings, sleep quality, nocturnal awakening frequency, and HRV as separate metrics.

Does CBD oil help with cardiovascular disease sleep problems?

CBD oil addresses several mechanisms driving cardiovascular sleep disruption — particularly cardiac anxiety and nocturnal hypervigilance (5-HT1A amygdala-reactivity reduction), the ANS parasympathetic deficit driving nocturnal blood pressure non-dipping (documented HRV-improving vagal promotion), HPA hyperactivation from cardiac stress (cortisol normalization), and the sympathetic overdrive that compounds both non-dipping and cardiac anxiety. For the physical cardiac mechanisms (orthopnea from heart failure, nocturnal angina from ischemia), CBD does not treat the underlying cardiac physiology and cannot substitute for physician-optimized cardiac medications. The most tractable cardiovascular sleep disruption mechanisms for CBD are the anxiety, sympathetic, and HPA components — where CBD's mechanisms are most evidence-grounded and address genuine pathological drivers rather than masking symptoms. All cardiac patients must disclose CBD use to their cardiologist before initiating, as cardiac medications include some of the most CYP-sensitive, narrow-therapeutic-index drugs in medicine, and warfarin interaction is life-critically important to manage with monitored INR adjustment.

Can CBD oil interact with heart medications?

Yes — CBD oil has clinically significant interactions with multiple cardiac medications through CYP enzyme inhibition, and cardiologist disclosure is mandatory before initiating. The most critical: warfarin (CYP2C9 substrate — CBD elevates warfarin plasma levels, increasing INR and bleeding risk; documented in human case reports; requires increased INR monitoring during CBD initiation). Direct oral anticoagulants (apixaban, rivaroxaban — CYP3A4 and P-gp substrates; CBD inhibits both). Antiarrhythmics: amiodarone (complex multi-CYP interaction — cardiologist oversight required); flecainide and propafenone (CYP2D6 substrates). Beta-blockers: metoprolol and carvedilol (CYP2D6 substrates — CBD may increase beta-blockade, causing bradycardia or excessive BP lowering). Statins: simvastatin and atorvastatin (CYP3A4 substrates — CBD may increase myopathy risk). Digoxin (P-gp substrate — CBD P-gp inhibition may elevate digoxin levels). Lower-interaction cardiac medications: atenolol (not CYP-metabolized), ACE inhibitors (not CYP-metabolized), pravastatin/rosuvastatin (minimal CYP3A4). Cardiologist disclosure allows appropriate monitoring to be established for each specific medication combination — the interactions are manageable with physician oversight, not reasons to avoid CBD entirely.

Does CBD oil help with high blood pressure during sleep?

CBD oil addresses nocturnal hypertension and blood pressure non-dipping primarily through its ANS parasympathetic-promoting mechanism. Normal nocturnal blood pressure dipping (10–20% BP reduction during sleep) requires a parasympathetic shift during sleep that reduces sympathetic vascular tone — when this parasympathetic shift is insufficient (non-dipping), nocturnal BP remains elevated. CBD's documented HRV improvement and vagal tone promotion (through 5-HT1A locus coeruleus suppression and CB1 hypothalamic ANS regulation) directly addresses the ANS substrate of non-dipping. Human studies have documented acute blood pressure reduction following CBD administration in healthy subjects; the sustained effect on nocturnal BP dipping in hypertensive patients has not been established in clinical trials. HPA normalization (cortisol-driven sympathetic activation reduction) and CB1 endothelial vasodilation (NO-mediated) contribute complementary mechanisms. The honest expectation: CBD may modestly improve nocturnal BP dipping and reduce the sympathetic component of nocturnal hypertension — a meaningful outcome given that non-dipping is an independent cardiovascular mortality predictor — without replacing antihypertensive medications as the primary BP management intervention. Monitor blood pressure during CBD initiation, particularly with antihypertensive polypharmacy, for additive hypotensive effects.

Is CBD oil safe for people with heart failure?

CBD oil can be considered by people with heart failure under cardiologist supervision, but with important context about what CBD can and cannot address. Heart failure's primary sleep disruption mechanisms — orthopnea from pulmonary congestion, paroxysmal nocturnal dyspnea, Cheyne-Stokes respiration — are driven by cardiac output inadequacy and volume overload that require physician-optimized heart failure medications (diuretics, ACE inhibitors/ARBs, beta-blockers, mineralocorticoid antagonists, SGLT2 inhibitors, ARNI) and, where indicated, device therapy (cardiac resynchronization, ICD). CBD does not address these physiology-driven mechanisms. What CBD may address in heart failure: the cardiac anxiety and nocturnal hypervigilance (5-HT1A mechanism), the HPA stress activation from living with heart failure (cortisol normalization), and the ANS sympathetic overdrive (vagal promotion) that is a pathological mechanism in HF progression. Heart failure patients have complex drug regimens with multiple CYP-sensitive medications (metoprolol/carvedilol CYP2D6; spironolactone CYP3A4; potentially digoxin P-gp); cardiologist disclosure of CBD and medication interaction review is mandatory before initiation. The conservative initiation protocol (10 mg starting dose, gradual titration) is particularly important in heart failure where hemodynamic stability is sensitive to any new agent.

Can CBD oil help with cardiac anxiety and nighttime palpitations?

CBD oil's 5-HT1A mechanism is specifically well-matched to the cardiac anxiety and nocturnal hypervigilance that many post-cardiac-event patients experience. The 5-HT1A partial agonism reduces amygdala reactivity — the amygdala-driven hypervigilant monitoring of cardiac sensations (heartbeat awareness, symptom amplification, palpitation anxiety) that maintains the cardiac anxiety loop. By reducing amygdala reactivity to cardiac sensations, CBD's 5-HT1A mechanism reduces the nocturnal hypervigilance that prevents sleep onset and causes arousals from minor cardiac sensation detection. For palpitations specifically: many palpitations are benign (ectopic beats, minor arrhythmias) that become subjectively intolerable in the sympathetically-sensitized, anxiety-amplified state of cardiac anxiety — CBD's anxiety and sympathetic reduction may make the same palpitations less symptomatic. For adrenergic atrial fibrillation (AF triggered by sympathetic activation), CBD's sympathetic-reducing ANS and HPA mechanisms may modestly reduce trigger frequency. Important: new or worsening palpitations, palpitations with symptoms (lightheadedness, chest pain, presyncope), or any change in palpitation pattern always warrants physician evaluation — cardiac anxiety is a real condition but palpitations can indicate medically important arrhythmias that require evaluation before attributing them to anxiety.

Does CBD oil affect heart rate or heart rhythm?

CBD oil's cardiovascular effects on heart rate are primarily mediated through ANS parasympathetic promotion — increased vagal tone generally reduces resting heart rate modestly and increases HRV. In healthy subjects, CBD tends to produce a mild parasympathomimetic cardiac effect (modest heart rate reduction from increased vagal tone, improved HRV). In patients with elevated resting heart rate from sympathetic overdrive (common in anxiety, heart failure, and post-MI), this vagal-promoting effect may produce beneficial modest heart rate reduction. For atrial fibrillation patients on rate control therapy (beta-blockers, calcium channel blockers, or digoxin for rate control): CBD's vagal-promoting mechanism is generally complementary to rate control strategy, and the parasympathetic effect may support rate control — but this also means the combined rate-lowering effect of rate control medication plus CBD's vagal promotion requires monitoring for excessive bradycardia, particularly with metoprolol or diltiazem where CYP interactions may also elevate medication levels. CBD does not have antiarrhythmic properties in the medical sense — it does not block specific ion channels targeted by antiarrhythmic drugs — but its sympathetic-reducing mechanism may reduce adrenergic arrhythmia triggers. Any patient with a history of significant arrhythmia should discuss CBD with their cardiologist specifically regarding electrophysiological risk before initiating.

Does CBD oil interact with warfarin?

Yes — the CBD-warfarin interaction is the most clinically significant drug interaction in this entire sleep series and requires mandatory management. CBD inhibits CYP2C9, the primary enzyme metabolizing warfarin (the S-enantiomer, which has 3–5 times the anticoagulant activity of R-warfarin). When CBD inhibits CYP2C9, warfarin metabolism slows, plasma warfarin levels rise, and INR increases — elevating bleeding risk. This interaction has been documented in human case reports, not just preclinical prediction, making it a clinically established interaction rather than a theoretical concern. The key variables determining interaction magnitude: CBD dose (higher doses inhibit CYP2C9 more potently), warfarin dose (higher warfarin doses leave more substrate for CYP inhibition to affect), and individual CYP2C9 genetic variation. The management protocol: anticoagulation clinic disclosure before starting CBD; INR monitoring every 3–5 days for the first 2–4 weeks of CBD initiation (versus standard weekly or biweekly monitoring); warfarin dose reduction if INR rises above therapeutic range (physician decision); establishment of the new stable CBD dose as a new baseline for INR management going forward. Once a stable CBD dose is established and INR is re-stabilized at that dose, monitoring returns to the usual schedule. This interaction is manageable — it does not preclude warfarin patients from using CBD — but requires physician-supervised INR management throughout CBD titration.

Can CBD oil lower blood pressure too much for cardiac patients?

CBD's blood pressure effects are generally modest — the documented acute antihypertensive effect in healthy subjects is approximately 6 mmHg systolic reduction in some studies, reflecting its vasodilatory CB1/endothelial and ANS parasympathetic mechanisms. For most cardiac patients on antihypertensive monotherapy, this modest additional antihypertensive effect is unlikely to cause symptomatic hypotension. The scenarios requiring more careful monitoring: cardiac patients on antihypertensive polypharmacy (multiple antihypertensive agents) where the combined BP-lowering effect may be more pronounced; patients with autonomic dysfunction (diabetic autonomic neuropathy, heart failure with reduced ejection fraction) where compensatory mechanisms for blood pressure are already impaired; and older patients with already low normal blood pressure where further reduction toward orthostatic hypotension threshold is clinically relevant. Monitor for orthostatic hypotension symptoms (dizziness upon standing, lightheadedness) during CBD initiation in any cardiac patient on antihypertensives — measuring sitting and standing blood pressure during the first 2–4 weeks of CBD is a reasonable precaution. If significant hypotensive symptoms develop, dose reduction and physician consultation are appropriate before continuing CBD titration.

How long does CBD oil take to improve cardiovascular sleep problems?

The timeline for cardiovascular sleep improvement with CBD oil varies by mechanism and cardiac condition. Cardiac anxiety improvement (5-HT1A mechanism — the most common and most CBD-tractable cardiovascular sleep mechanism) typically begins at 4–6 weeks of consistent daily dosing. ANS HRV improvement — trackable with a wearable heart rate variability monitor — typically appears at 6–8 weeks. Nocturnal blood pressure dipping improvement, if occurring, would be detectable with ambulatory 24-hour blood pressure monitoring at 8–12 weeks. CB2 vascular anti-inflammatory effects accumulate over 12+ weeks. The minimum evaluation period for cardiovascular patients is 12 weeks, with physician-monitored INR (for warfarin) or cardiac medication level checks during this period. The cardiac anxiety mechanism should show clear improvement by 8 weeks if CBD's 5-HT1A mechanism is addressing this component of sleep disruption — if no improvement in anxiety ratings and sleep onset ease after 8 weeks at the established therapeutic dose, the primary sleep disruption mechanism may be more physical (orthopnea, ischemic, arrhythmia) than anxiety-mediated, and the cardiac management strategy should be reviewed with the cardiologist.

Can CBD oil help with sleep after a heart attack?

Post-myocardial infarction (post-MI) sleep disruption involves several mechanisms that CBD oil addresses: post-MI cardiac anxiety and hypervigilance (5-HT1A amygdala-reactivity reduction — particularly relevant for the nocturnal hypervigilance that is extremely common in the first 6–12 months post-MI, when fear of recurrent event dominates nighttime experience); HPA hyperactivation from the acute stress of MI and ongoing cardiac recovery (cortisol normalization — elevated cortisol post-MI compounds the HPA-driven sympathetic activation that already increases post-MI cardiovascular risk); ANS sympathetic overdrive (post-MI sympathetic hyperactivation from baroreflex dysregulation and cardiac remodeling — CBD's vagal-promoting mechanism provides modest complementary parasympathetic support alongside beta-blockers and cardiac rehabilitation); and the inflammatory atherosclerotic substrate that precipitated the MI (CB2 vascular anti-inflammatory mechanism — addressing the ongoing plaque and endothelial inflammation that drives recurrent event risk). Mandatory context: post-MI management requires strict adherence to the evidence-based medication protocol (dual antiplatelet therapy, statin, beta-blocker, ACE inhibitor/ARB); CBD does not substitute for any post-MI medication. CYP interactions with post-MI medications (particularly CYP2C9 interactions with any CYP2C9-metabolized agent in the regimen) require cardiologist disclosure. Cardiac rehabilitation, which improves post-MI ANS function, HRV, and sleep quality through exercise training, is the most evidence-based post-MI sleep intervention and should be prioritized alongside any CBD consideration.

Medical Disclaimer

This article is for informational and educational purposes only. It is not intended to diagnose, treat, cure, or prevent coronary artery disease, heart failure, hypertension, atrial fibrillation, myocardial infarction, or any other cardiovascular condition. CBD oil is not a cardiac medication and does not replace physician-supervised cardiovascular management, prescribed cardiac medications, or emergency medical care for acute cardiac symptoms. The statements in this article have not been evaluated by the Food and Drug Administration. Cardiologist or prescribing physician disclosure is mandatory before initiating CBD for any patient taking cardiac medications, particularly warfarin (INR monitoring required), direct oral anticoagulants, antiarrhythmics, beta-blockers, statins, or digoxin. The warfarin-CBD interaction is clinically documented and requires increased INR monitoring during CBD initiation; the magnitude and management of other cardiac drug interactions require individual physician assessment. If you experience chest pain, palpitations, severe shortness of breath, syncope, or other acute cardiac symptoms, seek emergency medical care immediately — do not attempt to manage acute cardiac symptoms with CBD or any supplement. Acute cardiac symptoms are a medical emergency requiring immediate professional evaluation. Individual responses to CBD vary significantly. The cardiovascular mechanisms and interaction profiles described in this article represent the best available medical knowledge and mechanism-based extrapolation; clinical trial evidence specifically in cardiovascular sleep disruption populations is limited.